Page 94 - GALENIKA MEDICAL JOURNAL

10. Webert KT. Aldosterone in congestive heart
failure. N Engl J Med. 2001;345:1689.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.
The effect of spironolactone on morbidity and mortality in patients
with severe heart failure. Randomized Aldactone Evaluation
Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.
12. Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos
G, et al. Interplay of Mineralocorticoid Receptor Antagonists
and Empagliflozin in Heart Failure: EMPEROR-Reduced.
J Am Coll Cardiol. 2021 Mar 23;77(11):1397-407.
13. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et
al; TOPCAT Investigators. Influence of ejection fraction on outcomes
and efficacy of spironolactone in patients with heart failure with
preserved ejection fraction. Eur Heart J. 2016;37:455-62.
14. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E,
Böhm M, et al; EMPEROR-Preserved Trial Investigators.
Empagliflozin in Heart Failure with a Preserved Ejection
Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-61.

Konflikt interesa: Nema
Primljeno: 27. 02. 2022.
Prihvaćeno: 25. 03. 2022.
Onlajn: 30. 06. 2022.

94 DOI: 10.5937/Galmed2202090C